Bone health in postmenopausal women (PMW) with hormone-sensitive breast cancer (HSBC) receiving adjuvant aromatase inhibitor (AI) therapy

被引：2
|
作者：
Kalder, M. [1 ]
Hadji, P. [1 ]
机构：
[1] Univ Marburg, Marburg, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
10.1200/jco.2008.26.15_suppl.11556
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
11556
引用
下载
收藏
页数：1
相关论文
共 50 条
  • [1] Guidelines for bone health in postmenopausal women (PMW) with hormone-sensitive breast cancer (HSBC) receiving adjuvant aromatase inhibitor (AI) therapy
    Kalder, M.
    Hadji, P.
    EJC SUPPLEMENTS, 2008, 6 (07): : 78 - 78
  • [2] Choosing early adjuvant therapy for postmenopausal women with hormone-sensitive breast cancer: Aromatase inhibitors versus tamoxifen
    Carpenter, R.
    EJSO, 2008, 34 (07): : 746 - 755
  • [3] Aromatase inhibitor therapy: toxicities and management strategies in the treatment of postmenopausal women with hormone-sensitive early breast cancer
    Susan F. Dent
    Rania Gaspo
    Michelle Kissner
    Kathleen I. Pritchard
    Breast Cancer Research and Treatment, 2011, 126 : 295 - 310
  • [4] Aromatase inhibitor therapy: toxicities and management strategies in the treatment of postmenopausal women with hormone-sensitive early breast cancer
    Dent, Susan F.
    Gaspo, Rania
    Kissner, Michelle
    Pritchard, Kathleen I.
    BREAST CANCER RESEARCH AND TREATMENT, 2011, 126 (02) : 295 - 310
  • [5] Bone Health in Postmenopausal Women with Breast Cancer Receiving Aromatase Inhibitors
    Zikan, Vit
    Zimovjanova, Martina
    Petruzelka, Lubos
    Pribylova, Jana
    Cabinakova, Michaela
    Raskova, Maria
    JOURNAL OF BONE AND MINERAL RESEARCH, 2013, 28
  • [6] Efficacy of denosumab on bone mineral density in postmenopausal women with low bone mass and patients with breast cancer on adjuvant aromatase inhibitor (AI) therapy
    Bone, H. G.
    Ellis, G.
    Yuen, C. K.
    Kendler, D. L.
    Fan, M.
    Wang, H.
    Kim, D.
    Liu, Y.
    Dansey, R.
    Martin, J. San
    CALCIFIED TISSUE INTERNATIONAL, 2008, 82 : S38 - S38
  • [7] Sexual Dysfunction in Postmenopausal Women with Breast Cancer on Adjuvant Aromatase Inhibitor Therapy
    Lubian Lopez, Daniel Maria
    Butron Hinojo, Carmen Aisha
    Sanchez-Prieto, Manuel
    Mendoza, Nicolas
    Sanchez-Borrego, Rafael
    BREAST CARE, 2021, 16 (04) : 376 - 382
  • [8] Start strong or switch? Adjuvant endocrine strategies for postmenopausal women with hormone-sensitive breast cancer
    Tusquets Trias de Bes, Ignasi
    Tormo, Sonia Servitja
    Mestres, Joan Albanell
    BIOMEDICINE & PHARMACOTHERAPY, 2009, 63 (01) : 1 - 10
  • [9] An integrated analysis of zoledronic acid (ZA) for prevention of aromatase inhibitor associated bone loss (AIBL) in postmenopausal women (PMW) with early breast cancer (BCa) receiving adjuvant letrozole (LET)
    Brufsky, A.
    Bundred, N.
    Coleman, R.
    Lambert-Falls, R.
    Mena, R.
    Dong, M.
    Schenk, N.
    Lacerna, L.
    Perez, E.
    BREAST, 2007, 16 : S57 - S57
  • [10] An integrated analysis of zoledronic acid (ZA) for prevention of aromatase inhibitor associated bone loss (AIBL) in postmenopausal women (PMW) with early breast cancer (BCa) receiving adjuvant letrozole (LET).
    Brufsky, A.
    Bundred, N.
    Coleman, R.
    Lambert-Falls, R.
    Mena, R.
    Dong, M.
    Schenk, N.
    Lacerna, L.
    Perez, E.
    BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S25 - S25
12345